{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"MyMD Pharmaceuticals Begins Trading on Nasdaq - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"QhAaFTC92l\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/\">MyMD Pharmaceuticals Begins Trading on Nasdaq<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/embed\/#?secret=QhAaFTC92l\" width=\"600\" height=\"338\" title=\"&#8220;MyMD Pharmaceuticals Begins Trading on Nasdaq&#8221; &#8212; Market Newsdesk\" data-secret=\"QhAaFTC92l\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"MyMD Pharmaceuticals Begins Trading on Nasdaq Phase II Trial results expected by year end BALTIMORE&#8211;(BUSINESS WIRE)&#8211; MyMD Pharmaceuticals, Inc. (\u201cMYMD\u201d) is pleased to announce that its common shares will begin trading today, April 19th, on the NASDAQ Stock Market (\u201cNASDAQ\u201d) under the ticker symbol \u201cMYMD.\u201d MyMD Pharmaceuticals intends to focus on developing and commercializing novel immunotherapy pipeline assets, including MYMD-1, a first-in-class drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan. MyMD recently announced a Phase II trial that will initiate during the near term with results expected by year end. &#8220;The listing of our shares on the Nasdaq marks a significant milestone for the company, in combination with our upcoming phase II trial and &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"}